Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice
Autor: | Jer-Yuarn Wu, Bing-Mae Chen, Yi-Wen Chiu, Pei-Hua Yu, Tian-Lu Cheng, Daw-Yang Hwang, Tien-Ching Chang, And Steve Roffler, Yuan-Tsong Chen, Wen-Wei Lin |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
PEG-EPO
Methoxy polyethylene glycol-epoetin beta polyethylene glycol (PEG) Pharmaceutical Science Spleen methoxy polyethylene glycol-epoetin beta Polyethylene glycol macromolecular substances Pharmacology 030226 pharmacology & pharmacy Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine PEG ratio medicine anti-PEG antibodies biology Chemistry technology industry and agriculture Biological activity anemia medicine.anatomical_structure 030220 oncology & carcinogenesis Monoclonal biology.protein Erythropoiesis Antibody erythropoiesis |
Zdroj: | Pharmaceutics Volume 12 Issue 1 |
ISSN: | 1999-4923 |
DOI: | 10.3390/pharmaceutics12010015 |
Popis: | Pre-existing antibodies that bind polyethylene glycol are present in about 40% of healthy individuals. It is currently unknown if pre-existing anti-polyethylene glycol (PEG) antibodies can alter the bioactivity of pegylated drugs with a single long PEG chain, which represents the majority of newly developed pegylated medicines. Methoxy polyethylene glycol-epoetin beta (PEG-EPO) contains a single 30 kDa PEG chain and is used to treat patients suffering from anemia. We find that the pre-existing human anti-PEG IgM and IgG antibodies from normal donors can bind to PEG-EPO. The prevalence and concentrations of anti-PEG IgM and IgG antibodies were also higher in patients that responded poorly to PEG-EPO. Monoclonal anti-PEG IgM and IgG antibodies at concentrations found in normal donors blocked the biological activity of PEG-EPO to stimulate the production of new erythrocytes in mice and accelerated the clearance of 125I-PEG-EPO, resulting in PEG-EPO accumulation primarily in the liver and spleen. Accelerated clearance by the anti-PEG IgG antibody was mediated by the Fc portion of the antibody. Importantly, infusing higher doses of PEG-EPO could compensate for the inhibitory effects of anti-PEG antibodies, suggesting that pre-existing anti-PEG antibodies can be &ldquo dosed through.&rdquo Our study indicates that the bioactivity and therapeutic activity of PEG-EPO may be reduced in patients with elevated levels of pre-existing anti-PEG antibodies. New pegylated medicines with a single long PEG chain may also be affected in patients with high levels of anti-PEG antibodies. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |